Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Use of Newer DMTs in Pediatric MS Examined

Neurology; ePub 2018 Oct 17; Krysko, et al

Newer disease-modifying therapies (DMTs) are often used in pediatric multiple sclerosis (MS), and have similar short-term safety, tolerability, and side effect profiles as in adults, according to a recent study. Researchers conducted a cohort study including children with MS or clinically isolated syndrome (CIS) followed at 12 outpatient practices participating in the US Network of Pediatric MS Centers. DMT use, including duration, dose, and side effects, was analyzed. They found:

  • As of July 2017, 1,019 pediatric patients with MS (n=748) or CIS (n= 71) were enrolled (65% female, mean onset 13.0 ± 3.9 years, mean follow-up 3.5 ± 3.1 years, median 1.6 visits per year).
  • Of these, 78% (n=587) with MS and 11% (n=31) with CIS received DMT before age 18.
  • This consisted of at least 1 newer DMT in 42%.
  • Among 17%, the initial DMT prescribed was a newer agent.
  • Over the last 10 years, the use of newer agents has increased, particularly in those ≥12 years and to lesser extent in those <12 years.
  • The short-term side effect profiles of newer DMTs did not differ from those reported in adults.
Citation:

Krysko KM, Graves J, Rensel M, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. [Published online ahead of print October 17, 2018]. Neurology. doi:10.1212/WNL.0000000000006471.

This Week's Must Reads

Examining Brain Markers for Late-Onset Epilepsy, Neurology; ePub 2019 Jan 25; Johnson, et al

Hearing Loss Linked Cognitive Decline Risk in Men, Alzheimers Dement; ePub 2019 Jan 29; Curhan, et al

Brain Cholesterol Metabolism and PD Examined, Mov Disord; ePub 2019 Jan 25; Huang, et al

Sleep Behavior Disorder, Clinical Progression in PD, Parkinsonism Relat Disord; ePub 2019 Jan 29; Duarte Folle, et al

Spontaneous Subarachnoid Hemorrhage During Pregnancy, J Stroke Cerebrovasc Dis; ePub 2019 Jan 30; Limaye, et al

Must Reads in Multiple Sclerosis

Prevalence of Asthma in Persons with MS, Mult Scler Relat Disord; ePub 2018 Dec 11; Hill, et al

Normal-Appearing White Matter in MS Examined, Neuroradiology; ePub 2018 Dec 12; Yu, et al

MS Disease Burden: Which Symptoms Matter Most?, Mult Scler Relat Disord; 2018 Oct; Barin, et al

Retinal Layer Thickness and MS Conversion Risk, Mult Scler; ePub 2018 Dec 3; Filippatou, et al

Importance of Coping and QOL in People with MS, Int J MS Care; ePub 2018 Dec 6; Grech, et al